300 related articles for article (PubMed ID: 30131249)
1. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
Ma R; Yun CH
Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
[TBL] [Abstract][Full Text] [Related]
2. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule.
Deng G; Shen J; Yin M; McManus J; Mathieu M; Gee P; He T; Shi C; Bedel O; McLean LR; Le-Strat F; Zhang Y; Marquette JP; Gao Q; Zhang B; Rak A; Hoffmann D; Rooney E; Vassort A; Englaro W; Li Y; Patel V; Adrian F; Gross S; Wiederschain D; Cheng H; Licht S
J Biol Chem; 2015 Jan; 290(2):762-74. PubMed ID: 25391653
[TBL] [Abstract][Full Text] [Related]
4. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
Sharma H
Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
[TBL] [Abstract][Full Text] [Related]
5. Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity.
Xie X; Baird D; Bowen K; Capka V; Chen J; Chenail G; Cho Y; Dooley J; Farsidjani A; Fortin P; Kohls D; Kulathila R; Lin F; McKay D; Rodrigues L; Sage D; Touré BB; van der Plas S; Wright K; Xu M; Yin H; Levell J; Pagliarini RA
Structure; 2017 Mar; 25(3):506-513. PubMed ID: 28132785
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.
Gao M; Zhu H; Fu L; Li Y; Bao X; Fu H; Quan H; Wang L; Lou L
Cancer Sci; 2019 Oct; 110(10):3306-3314. PubMed ID: 31361380
[TBL] [Abstract][Full Text] [Related]
7. Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q.
Chen J; Yang J; Sun X; Wang Z; Cheng X; Lu W; Cai X; Hu C; Shen X; Cao P
Sci Rep; 2017 Nov; 7(1):16458. PubMed ID: 29184081
[TBL] [Abstract][Full Text] [Related]
8. Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
Chen D; Xia S; Zhang R; Li Y; Famulare CA; Fan H; Wu R; Wang M; Zhu AC; Elf SE; Su R; Dong L; Arellano M; Blum WG; Mao H; Lonial S; Stock W; Odenike O; Le Beau M; Boggon TJ; He C; Chen J; Gao X; Levine RL; Chen J
Mol Cell; 2021 Sep; 81(18):3833-3847.e11. PubMed ID: 34289383
[TBL] [Abstract][Full Text] [Related]
9. The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.
Chen J; Yang J; Cao P
Mini Rev Med Chem; 2016; 16(16):1344-1358. PubMed ID: 27292784
[TBL] [Abstract][Full Text] [Related]
10. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
Wang F; Travins J; DeLaBarre B; Penard-Lacronique V; Schalm S; Hansen E; Straley K; Kernytsky A; Liu W; Gliser C; Yang H; Gross S; Artin E; Saada V; Mylonas E; Quivoron C; Popovici-Muller J; Saunders JO; Salituro FG; Yan S; Murray S; Wei W; Gao Y; Dang L; Dorsch M; Agresta S; Schenkein DP; Biller SA; Su SM; de Botton S; Yen KE
Science; 2013 May; 340(6132):622-6. PubMed ID: 23558173
[TBL] [Abstract][Full Text] [Related]
12. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
[TBL] [Abstract][Full Text] [Related]
13. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic
Yen K; Travins J; Wang F; David MD; Artin E; Straley K; Padyana A; Gross S; DeLaBarre B; Tobin E; Chen Y; Nagaraja R; Choe S; Jin L; Konteatis Z; Cianchetta G; Saunders JO; Salituro FG; Quivoron C; Opolon P; Bawa O; Saada V; Paci A; Broutin S; Bernard OA; de Botton S; Marteyn BS; Pilichowska M; Xu Y; Fang C; Jiang F; Wei W; Jin S; Silverman L; Liu W; Yang H; Dang L; Dorsch M; Penard-Lacronique V; Biller SA; Su SM
Cancer Discov; 2017 May; 7(5):478-493. PubMed ID: 28193778
[TBL] [Abstract][Full Text] [Related]
14. Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Lee WY; Chen KC; Chen HY; Chen CY
Biomed Res Int; 2014; 2014():364625. PubMed ID: 24995286
[TBL] [Abstract][Full Text] [Related]
15. Recent advances of IDH1 mutant inhibitor in cancer therapy.
Tian W; Zhang W; Wang Y; Jin R; Wang Y; Guo H; Tang Y; Yao X
Front Pharmacol; 2022; 13():982424. PubMed ID: 36091829
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
17. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
18. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
Nassereddine S; Lap CJ; Haroun F; Tabbara I
Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
[TBL] [Abstract][Full Text] [Related]
19. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells.
Chen J; Yang J; Wei Q; Weng L; Wu F; Shi Y; Cheng X; Cai X; Hu C; Cao P
Cell Commun Signal; 2020 Apr; 18(1):55. PubMed ID: 32245484
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability.
Thomas D; Wu M; Nakauchi Y; Zheng M; Thompson-Peach CAL; Lim K; Landberg N; Köhnke T; Robinson N; Kaur S; Kutyna M; Stafford M; Hiwase D; Reinisch A; Peltz G; Majeti R
Cancer Discov; 2023 Feb; 13(2):496-515. PubMed ID: 36355448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]